Patents by Inventor Anthony A. Estrada

Anthony A. Estrada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic DLK inhibitors and uses thereof
    Patent number: 10131675
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • COMPOUND, COMPOSITIONS, AND METHODS
    Publication number: 20180327391
    Abstract: Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180282272
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20180208582
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 21, 2018
    Publication date: July 26, 2018
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Biheteroaryl compounds and uses thereof
    Patent number: 10028954
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos
  • 3-substituted pyrazoles and uses thereof
    Patent number: 10028942
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • Biheteroaryl compounds and uses thereof
    Patent number: 10010549
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180133219
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180118680
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20180099981
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 12, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions, and methods
    Patent number: 9932325
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 3, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20180051009
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 22, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions and methods
    Patent number: 9896458
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 20, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20180022759
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • TRICYCLIC DLK INHIBITORS AND USES THEREOF
    Publication number: 20170369510
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20170362206
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions and methods
    Patent number: 9815850
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 14, 2017
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20170226127
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 3, 2017
    Publication date: August 10, 2017
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • 3-SUBSTITUTED PYRAZOLES AND USES THEREOF
    Publication number: 20170087137
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • Substituted sulfonamide compounds
    Patent number: 9580411
    Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: February 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi